Ren X-R, Zhou L-J, Luo G-B, Lin B, Xu A
State Key Laboratory of Biocontrol, Department of Biochemistry, College of Life Sciences, Sun Yat-sen (Zhongshan) University, Guangzhou 510275, China.
J Viral Hepat. 2005 May;12(3):236-42. doi: 10.1111/j.1365-2893.2005.00587.x.
Hepatitis B virus (HBV) infection is a worldwide health problem. To determine whether RNA interference (RNAi) could inhibit ongoing HBV replication in 2.2.15 cells, we constructed shRNA-producing vector pU6P based on the mouse U6 RNA promoter and cloned 12 targeted sequences against HBV into the vector, resulting in a series of pU6-siHBV vectors. The recombinant vectors were transfected into 2.2.15 cells, HBsAg and HBeAg in cultured media were assayed using enzyme-linked immunosorbent assay at various days after transfection. The amount of HBV DNA in the culture medium was quantitated by real-time polymerase chain reaction. HBsAg and HBeAg expression were inhibited by 72.8 +/- 5.4% (P = 0.00003) and 55.8 +/- 6.2% (P = 0.000026), respectively, 4 days after transfection with pU6-siHBV5. The greatest inhibition of HBV DNA was decreased by approximately 1.9-fold (P = 0.013) on day 6 post transfection with pU6-siHBV11 compared with that of empty vector. No change was found for HBV protein expression and DNA replication on pU6-siGFP (negative control) transfected cells. Our data demonstrate that the transfection of HBV-targeted shRNA-producing vector in 2.2.15 cells could inhibit the HBV protein expression and HBV DNA replication specifically. RNAi may be considered as a potential antiviral approach for human HBV infection.
乙型肝炎病毒(HBV)感染是一个全球性的健康问题。为了确定RNA干扰(RNAi)是否能够抑制2.2.15细胞中正在进行的HBV复制,我们基于小鼠U6 RNA启动子构建了产生shRNA的载体pU6P,并将12个针对HBV的靶向序列克隆到该载体中,从而得到了一系列pU6-siHBV载体。将重组载体转染到2.2.15细胞中,在转染后的不同天数,使用酶联免疫吸附测定法检测培养基中的HBsAg和HBeAg。通过实时聚合酶链反应对培养基中的HBV DNA量进行定量。用pU6-siHBV5转染4天后,HBsAg和HBeAg的表达分别被抑制了72.8±5.4%(P = 0.00003)和55.8±6.2%(P = 0.000026)。与空载体相比,用pU6-siHBV11转染后第6天,HBV DNA的最大抑制率降低了约1.9倍(P = 0.013)。在转染pU6-siGFP(阴性对照)的细胞中,未发现HBV蛋白表达和DNA复制有变化。我们的数据表明,在2.2.15细胞中转染靶向HBV的产生shRNA的载体能够特异性地抑制HBV蛋白表达和HBV DNA复制。RNAi可能被认为是一种针对人类HBV感染的潜在抗病毒方法。